NEUROTROPHIC FACTORS AND NEURODEGENERATIVE DISEASES: A DELIVERY ISSUE

被引：27

作者：

Ruozi, B. ^{[1
]}

Belletti, D. ^{[1
]}

Bondioli, L. ^{[1
]}

De Vita, A. ^{[1
]}

Forni, F. ^{[1
]}

Vandelli, M. A. ^{[1
]}

Tosi, G. ^{[1
]}

机构：

[1] Univ Modena & Reggio Emilia, Dept Pharmaceut Sci, Modena, Italy

来源：

NEW PERSPECTIVES OF CENTRAL NERVOUS SYSTEM INJURY AND NEUROPROTECTION | 2012年 / 102卷

关键词：

NERVE GROWTH-FACTOR; BLOOD-BRAIN-BARRIER; AMYOTROPHIC-LATERAL-SCLEROSIS; NIGRAL DOPAMINERGIC-NEURONS; NEURAL PROGENITOR CELLS; FACTOR GENE-THERAPY; FACTOR PREVENTS DEGENERATION; MESENCHYMAL STEM-CELLS; MARROW STROMAL CELLS; GDNF-PRODUCING CELLS;

D O I：

10.1016/B978-0-12-386986-9.00009-0

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Neurotrophic factors (NTFs) represent one of the most stimulating challenge in neurodegenerative diseases, due to their potential in neurorestoring and neuroprotection. Despite the large number of proofs-of-concept and evidences of their activity, most of the clinical trials, mainly regarding Parkinson's disease and Alzheimer's disease, demonstrated several failures of the therapeutic intervention. A large number of researches were conducted on this hot topic of neuroscience, clearly evidencing the advantages of NTF approach, but evidencing the major limitations in its application. The inability in crossing the blood brain barrier and the lack of selectivity actually represent some of the most highlighted limits of NTFs-based therapy. In this review, beside an overview of NTF activity versus the main neuropathological disorders, a summary of the most relevant approaches, from invasive to noninvasive strategies, applied for improving NTF delivery to the central nervous systems is critically considered and evaluated.

引用

页码：207 / 247

页数：41

共 215 条

[1]

ADAMS P, 1988, AM J HUM GENET, V43, P695

[2] Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients [J].

Aebischer, P ;

Schluep, M ;

Deglon, N ;

Joseph, JM ;

Hirt, L ;

Heyd, B ;

Goddard, M ;

Hammang, JP ;

Zurn, AD ;

Kato, AC ;

Regli, F ;

Baetge, EE .

NATURE MEDICINE, 1996, 2 (06) :696-699

[3] Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease [J].

Åkerud, P ;

Canals, JM ;

Snyder, EY ;

Arenas, E .

JOURNAL OF NEUROSCIENCE, 2001, 21 (20) :8108-8118

[4] Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery [J].

Alavijeh M.S. ;

Chishty M. ;

Qaiser M.Z. ;

Palmer A.M. .

NeuroRX, 2005, 2 (4) :554-571

[5] Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases [J].

Alexi, T ;

Borlongan, CV ;

Faull, RLM ;

Williams, CE ;

Clark, RG ;

Gluckman, PD ;

Hughes, PE .

PROGRESS IN NEUROBIOLOGY, 2000, 60 (05) :409-470

[6] Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease [J].

Anderson, KD ;

Panayotatos, N ;

Corcoran, TL ;

Lindsay, RM ;

Wiegand, SJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (14) :7346-7351

[7] A UNIFYING HYPOTHESIS FOR THE CAUSE OF AMYOTROPHIC LATERAL SCLEROSIS, PARKINSONISM, AND ALZHEIMER-DISEASE [J].

APPEL, SH .

ANNALS OF NEUROLOGY, 1981, 10 (06) :499-505

[8]

ARAKAWA Y, 1990, J NEUROSCI, V10, P3507

[9] Glial cell line-derived neurotrophic factor attenuates the excitotoxin-induced behavioral and neurochemical deficits in a rodent model of Huntington's disease [J].

Araujo, DM ;

Hilt, DC .

NEUROSCIENCE, 1997, 81 (04) :1099-1110

[10] Repairing the parkinsonian brain with neurotrophic factors [J].

Aron, Liviu ;

Klein, Ruediger .

TRENDS IN NEUROSCIENCES, 2011, 34 (02) :88-100

← 1 2 3 4 5 6 7 8 9 10 →